Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Effectiveness of a New Malaria Vaccine Candidate by Infecting Vaccinated Volunteers With Malaria Parasites

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 10.0

Eligibility Criteria:
Inclusion Criteria:~* Able and willing (in the Investigator's opinion) to comply with all study requirements~* Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner~* For females only: willingness to practise effective contraception throughout the study~* Agreement to refrain from blood donation during the course of the study~* Written informed consent~Exclusion Criteria:~* Participation in another research study involving an investigational product in the 30 days preceding enrolment, or planned use during the study period.~* Prior receipt of an investigational malaria vaccine encoding ME-TRAP or any other investigational vaccine likely to impact on interpretation of the trial data~* Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate~* Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed)~* Pregnancy, lactation or intention to become pregnant during the study~* Contraindication to both anti-malarial drugs (Riamet® and chloroquine)~  o concomitant use with other drugs known to cause QT-interval prolongation, ( e.g. macrolides, quinolones, amiodarone etc)~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products, Kathon.~* History of clinically significant contact dermatitis~* Any history of anaphylaxis in reaction to vaccination~* History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)~* History of serious psychiatric condition~* Any other serious chronic illness requiring hospital specialist supervision~* Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week~* Suspected or known injecting drug abuse~* Seropositive for hepatitis B surface antigen (HBsAg)~* Seropositive for hepatitis C virus (antibodies to HCV)~* Seropositive for simian adenovirus 63 (antibodies to AdCh63) at a titre \> 1: 200 ( EXCEPT CONTROL VOLUNTEERS)~* Any other significant disease, disorder or finding, which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or may influence the result of the study, or the volunteer's ability to participate in the study.~* History of clinical P. falciparum malaria~* Travel to a malaria endemic region during the study period or within the previous six months~* Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis~* Any other finding which in the opinion of the investigators would significantly increase the risk of having an adverse outcome from participating in the protocol or impair interpretation of the study data.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: EXPERIMENTAL): AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 3 weeks after boost
- Group 2 (Type: EXPERIMENTAL): AdCh63 ME-TRAP alone followed by sporozoite challenge 3 weeks later
- Group 3 (Type: EXPERIMENTAL): Non-vaccinated Control for Groups 1 and 2 challenged with sporozoite
- Group 4 (Type: EXPERIMENTAL): AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 11 weeks after boost
- Group 5 (Type: EXPERIMENTAL): AdCh63 ME-TRAP prime followed by MVA ME-TRAP boost 8 weeks later and challenged by sporozoite 3 weeks after boost
- Group 6 (Type: EXPERIMENTAL): Protected volunteers from Group 1 re-challenged with sporozoite after 6 months
- Group 7 (Type: EXPERIMENTAL): Non vaccinated control for Groups 4-6, 8-10 challenged with sporozoite
- Group 8 (Type: EXPERIMENTAL): 3 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 8 weeks interval each followed by sporozoite challenge 3 weeks after last vaccination
- Group 9 (Type: EXPERIMENTAL): 2 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 8 weeks interval followed by sporozoite challenge 3 weeks after last vaccination
- Group 10 (Type: EXPERIMENTAL): 3 vaccinations of mixture formulation AdCh63 ME-TRAP and MVA ME-TRAP give at 4 weeks interval each followed by sporozoite challenge 3 weeks after last vaccination

Based on this trial design, predict the completion outcome and termination type (if applicable).